Uterine Leiomyomata

Women and Health

Volumn , Issue , 2013, Pages 285-305

  Wise, Lauren A ^a   Laughlin Tommaso, Shannon K ^b  

^a BOSTON UNIVERSITY   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884119006     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384978-6.00019-4     Document Type: Chapter

References (240)

1. Merrill R.M. Hysterectomy surveillance in the United States, 1997 through 2005. Med Sci Monit 2008, 14:CR24-CR31.
2. Cardozo E.R., Clark A.D., Banks N.K., Henne M.B., Stegmann B.J., Segars J.H. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 2012, 206(211):e1-e9.
3. Becker E.R. National trends and determinants of hospitalization costs and lengths-of-stay for uterine fibroids procedures. J Health Care Finance 2007, 33:1-16.
4. Whiteman M.K., Kuklina E., Jamieson D.J., Hillis S.D., Marchbanks P.A. Inpatient hospitalization for gynecological disorders in the United States. Am J Obstet Gynecol 2010, 202(541):e1-e6.
5. Laughlin S.K., Schroeder J.C., Baird D.D. New directions in the epidemiology of uterine fibroids. Semin Reprod Med 2010, 28:204-217.
6. Flake G.P., Andersen J., Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003, 111:1037-1054.
7. Buttram V.C., Reiter R.C. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981, 36:433-445.
8. Rein M.S., Friedman A.J., Barbieri R.L., Pavelka K., Fletcher J.A., Morton C.C. Cytogenetic abnormalities in uterine leiomyomata. Obstet Gynecol 1991, 77:923-926.
9. Stewart E.A., Morton C.C. The genetics of uterine leiomyomata: what clinicians need to know. Obstet Gynecol 2006, 107:917-921.
10. Schoenberg Fejzo M., Ashar H.R., Krauter K.S., Powell W.L., Rein M.S., Weremowicz S., et al. Translocation breakpoints upstream of the HMGIC gene in uterine leiomyomata suggest dysregulation of this gene by a mechanism different from that in lipomas. Genes Chromosomes Cancer 1996, 17:1-6.
11. Williams A.J., Powell W.L., Collins T., Morton C.C. HMGI(Y) expression in human uterine leiomyomata. Involvement of another high-mobility group architectural factor in a benign neoplasm. Am J Pathol 1997, 150:911-918.
12. Bustin M., Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 1996, 54:35-100.
13. Brosens I., Deprest J., Dal Cin P., Van den Berghe H. Clinical significance of cytogenetic abnormalities in uterine myomas. Fertil Steril 1998, 69:232-235.
14. Christacos N.C., Quade B.J., Dal Cin P., Morton C.C. Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histological features. Genes Chromosomes Cancer 2006, 45:304-312.
15. Giuntoli R.L., Gostout B.S., DiMarco C.S., Metzinger D.S., Keeney G.L. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior. J Reprod Med 2007, 52:1001-1010.
16. Parker W.H., Fu Y.S., Berek J.S. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994, 83:414-418.
17. ACOG Practice Bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol 2008;112:387-400.
18. Rosati P., Exacoustos C., Mancuso S. Longitudinal evaluation of uterine myoma growth during pregnancy. A sonographic study. J Ultrasound Med 1992, 11:511-515.
19. Aharoni A., Reiter A., Golan D., Paltiely Y., Sharf M. Patterns of growth of uterine leiomyomas during pregnancy. A prospective longitudinal study. Br J Obstet Gynaecol 1988, 95:510-513.
20. Peddada S.D., Laughlin S.K., Miner K., Guyon J.P., Haneke K., Vahdat H.L., et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci USA 2008, 105:19887-19892.
21. Baird D.D., Garrett T.A., Laughlin S.K., Davis B., Semelka R.C., Peddada S.D. Short-term change in growth of uterine leiomyoma: tumor growth spurts. Fertil Steril 2011, 95:242-246.
22. Lev-Toaff A.S., Coleman B.G., Arger P.H., Mintz M.C., Arenson R.L., Toaff M.E. Leiomyomas in pregnancy: sonographic study. Radiology 1987, 164:375-380.
23. Hammoud A.O., Asaad R., Berman J., Treadwell M.C., Blackwell S., Diamond M.P. Volume change of uterine myomas during pregnancy: do myomas really grow?. J Minim Invasive Gynecol 2006, 13:386-390.
24. Wegienka G., Baird D.D., Hertz-Picciotto I., Harlow S.D., Steege J.F., Hill M.C., et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol 2003, 101:431-437.
25. Kjerulff K.H., Langenberg P., Seidman J.D., Stolley P.D., Guzinski G.M. Uterine leiomyomas: racial differences in severity, symptoms, and age at diagnosis. J Reprod Med 1996, 41:483-490.
26. Lippman S.A., Warner M., Samuels S., Olive D., Vercellini P., Eskenazi B. Uterine fibroids and gynecological pain symptoms in a population-based study. Fertil Steril 2003, 80:1488-1494.
27. Marshall L.M., Spiegelman D., Barbieri R.L., Goldman M.B., Manson J.E., Colditz G.A., et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997, 90:967-973.
28. Wise L.A., Palmer J.R., Stewart E.A., Rosenberg L. Age-specific incidence rates for self-reported uterine leiomyomata in the black women's health study. Obstet Gynecol 2005, 105:563-568.
29. Baird D.D., Dunson D.B., Hill M.C., Cousins D., Schectman J.M. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003, 188:100-107.
30. Loutradis D., Antsaklis A., Creatsas G., Hatzakis A., Kanakas N., Gougoulakis A., et al. The validity of gynecological ultrasonography. Gynecol Obstet Invest 1990, 29:47-50.
31. Fedele L., Bianchi S., Dorta M., Brioschi D., Zanotti F., Vercellini P. Transvaginal ultrasonography versus hysteroscopy in the diagnosis of uterine submucous myomas. Obstet Gynecol 1991, 77:745-748.
32. Dueholm M., Lundorf E., Hansen E.S., Ledertoug S., Olesen F. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol 2002, 186:409-415.
33. Schwartz S.M., Marshall L.M., Baird D.D. Epidemiological contributions to understanding the etiology of uterine leiomyomata. Environ Health Perspect 2000, 108:821-827.
34. Wu J.M., Wechter M.E., Geller E.J., Nguyen T.V., Visco A.G. Hysterectomy rates in the United States, 2003. Obstet Gynecol 2007, 110:1091-1095.
35. D'Aloisio A.A., Baird D.D., DeRoo L.A., Sandler D.P. Association of intrauterine and early-life exposures with diagnosis of uterine leiomyomata by 35 years of age in the sister study. Environ Health Perspect 2010, 118:375-381.
36. Wise L.A., Palmer J.R., Harlow B.L., Spiegelman D., Stewart E.A., Adams-Campbell L.L., et al. Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the black women's health study. Hum Reprod 2004, 19:1746-1754.
37. Borgfeldt C., Andolf E. Transvaginal ultrasonographic findings in the uterus and endometrium: low prevalence of leiomyoma in a random sample of women age 25-40 years. Acta Obstet Gynecol Scand 2000, 79:202-207.
38. Laughlin S.K., Baird D.D., Savitz D.A., Herring A.H., Hartmann K.E. Prevalence of uterine leiomyomas in the first trimester of pregnancy: an ultrasound-screening study. Obstetrics & Gynecology 2009, 113:630-635.
39. Laughlin S.K., Herring A.H., Savitz D.A., Olshan A.F., Fielding J.R., Hartmann K.E., et al. Pregnancy-related fibroid reduction. Fertil Steril 2010, 94:2421-2423.
40. Bower J.K., Schreiner P.J., Sternfeld B., Lewis C.E. Black-white differences in hysterectomy prevalence: the CARDIA study. Am J Public Health 2009, 99:300-307.
41. Eskenazi B., Warner M., Samuels S., Young J., Gerthoux P.M., Needham L., et al. Serum dioxin concentrations and risk of uterine leiomyoma in the Seveso women's health study. Am J Epidemiol 2007, 166:79-87.
42. Velebil P., Wingo P.A., Xia Z., Wilcox L.S., Peterson H.B. Rate of hospitalization for gynecological disorders among reproductive-age women in the United States. Obstet Gynecol 1995, 86:764-769.
43. Brett K.M., Marsh J.V., Madans J.H. Epidemiology of hysterectomy in the United States: demographic and reproductive factors in a nationally representative sample. J Womens Health 1997, 6:309-316.
44. Templeman C., Marshall S.F., Clarke C.A., Henderson K.D., Largent J., Neuhausen S., et al. Risk factors for surgically removed fibroids in a large cohort of teachers. Fertil Steril 2009, 92:1436-1446.
45. Ross R.K., Pike M.C., Vessey M.P., Bull D., Yeates D., Casagrande J.T. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J Clin Res Ed 1986, 293:359-362.
46. Reed S.D., Cushing-Haugen K.L., Daling J.R., Scholes D., Schwartz S.M. Postmenopausal estrogen and progestogen therapy and the risk of uterine leiomyomas. Menopause 2004, 11:214-222.
47. Kjerulff K.H., Langenberg P., Guzinski G.M. The socioeconomic correlates of hysterectomies in the United States. Am J Public Health 1993, 83:106-108.
48. Luoto R., Kaprio J., Rutanen E.M., Taipale P., Perola M., Koskenvuo M. Heritability and risk factors of uterine fibroids - the Finnish twin cohort study. Maturitas 2000, 37:15-26.
49. Becker E.R., Spalding J., DuChane J., Horowitz I.R. Inpatient surgical treatment patterns for patients with uterine fibroids in the United States, 1998-2002. J Natl Med Assoc 2005, 97:1336-1342.
50. Viswanathan M., Hartmann K., McKoy N., Stuart G., Rankins N., Thieda P., et al. Management of uterine fibroids: an update of the evidence. Evid Rep Technol Assess (Full Rep) 2007, 154:1-122.
51. Asada H., Yamagata Y., Taketani T., Matsuoka A., Tamura H., Hattori N., et al. Potential link between estrogen receptor-alpha gene hypomethylation and uterine fibroid formation. Mol Hum Reprod 2008, 14:539-545.
52. Andersen A., Barbieri R.L. Abnormal gene expression in uterine leiomyomas. J Soc Gynecol Invest 1995, 2:663-672.
53. Sahin K., Ozercan R., Onderci M., Sahin N., Gursu M.F., Khachik F., et al. Lycopene supplementation prevents the development of spontaneous smooth muscle tumors of the oviduct in Japanese quail. Nutr Cancer 2004, 50:181-189.
54. Walker C.L., Cesen-Cummings K., Houle C., Baird D., Barrett J.C., Davis B. Protective effect of pregnancy for development of uterine leiomyoma. Carcinogenesis 2001, 22:2049-2052.
55. Munday J.S., Stedman N.L. Uterine leiomyomas in two Vietnamese pot-bellied pigs (Sus scrofa). Vet Pathol 2002, 39:580-583.
56. Blin C., L'Horset F., Romagnolo B., Colnot S., Lambert M., Thomasset M., et al. Functional and growth properties of a myometrial cell line derived from transgenic mice: effects of estradiol and antiestrogens. Endocrinology 1996, 137:2246-2253.
57. Bullerdiek J. Leiomyoma - do viruses play the main role?. Genes Chromosomes Cancer 1999, 26:181.
58. Romagnolo B., Molina T., Leroy G., Blin C., Porteux A., Thomasset M., et al. Estradiol-dependent uterine leiomyomas in transgenic mice. J Clin Invest 1996, 98:777-784.
59. Friel A.M., Growdon W.B., McCann C.K., Olawaiye A.B., Munro E.G., Schorge J.O., et al. Mouse models of uterine corpus tumors: clinical significance and utility. Front Biosci (Elite Ed) 2010, 2:882-905.
60. Andersen J. Growth factors and cytokines in uterine leiomyomas. Seminar Reprod Endocrinol 1996, 14:269-282.
61. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008, 22:571-588.
62. Bulun S.E., Imir G., Utsunomiya H., Thung S., Gurates B., Tamura M., et al. Aromatase in endometriosis and uterine leiomyomata. J Steroid Biochem Mol Biol 2005, 95:57-62.
63. Sadan O., van Iddekinge B., van Gelderen C.J., Savage N., Becker P.J., van der Walt L.A., et al. Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometrium. Ann Clin Biochem 1987, 24(Pt 3):263-267.
64. Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril 2010;93:192-198.
65. Wu T., Chen X., Xie L. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev 2007, 4:CD005287.
66. Wise L.A., Palmer J.R., Rowlings K., Kaufman R.H., Herbst A.L., Noller K.L., et al. Risk of benign gynecological tumors in relation to prenatal diethylstilbestrol exposure. Obstet Gynecol 2005, 105:167-173.
67. Di X., Yu L., Moore A.B., Castro L., Zheng X., Hermon T., et al. A low concentration of genistein induces estrogen receptor-alpha and insulin-like growth factor-I receptor interactions and proliferation in uterine leiomyoma cells. Hum Reprod 2008, 23:1873-1883.
68. Howe S.R., Gottardis M.M., Everitt J.I., Goldsworthy T.L., Wolf D.C., Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol 1995, 146:1568-1579.
69. Howe S.R., Gottardis M.M., Everitt J.I., Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 1995, 136:4996-5003.
70. Friedman A.J., Daly M., Juneau-Norcross M., Gleason R., Rein M.S., LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. Hum Reprod 1994, 9:1618-1625.
71. Rein M.S. Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 2000, 108(Suppl. 5):791-793.
72. Kawaguchi K., Fujii S., Konishi I., Nanbu Y., Nonogaki H., Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989, 160:637-641.
73. Lamminen S., Rantala I., Helin H., Rorarius M., Tuimala R. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol Obstet Invest 1992, 34:111-114.
74. Matsuo H., Maruo T., Samoto T. Increased expression of bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 1997, 82:293-299.
75. Tiltman A. The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Path 1985, 4:89-96.
76. Murphy A.A., Morales A.J., Kettel L.M., Yen S.S. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 1995, 64:187-190.
77. Bagaria M., Suneja A., Vaid N.B., Guleria K., Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust NZJ Obstet Gynaecol 2009, 49:77-83.
78. Spitz I.M. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009, 21:318-324.
79. Baird D.D., Travlos G., Wilson R., Dunson D.B., Hill M.C., D'Aloisio A.A., et al. Uterine leiomyomata in relation to insulin-like growth factor-I, insulin, and diabetes. Epidemiology 2009, 20:604-610.
80. Chegini N. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med 2010, 28:180-203.
81. Leppert P.C., Catherino W.H., Segars J.H. A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obstet Gynecol 2006, 195:415-420.
82. Arslan A.A., Gold L.I., Mittal K., Suen T.C., Belitskaya-Levy I., Tang M.S., et al. Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum Reprod 2005, 20:852-863.
83. Lee B.S., Nowak R.A. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab 2001, 86:913-920.
84. Malik M., Norian J., McCarthy-Keith D., Britten J., Catherino W.H. Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Semin Reprod Med 2010, 28:169-179.
85. Cramer S.F., Mann L., Calianese E., Daley J., Williamson K. Association of seedling myomas with myometrial hyperplasia. Hum Pathol 2009, 40:218-225.
86. Mashal R.D., Fejzo M.L., Friedman A.J., Mitchner N., Nowak R.A., Rein M.S., et al. Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata. Genes Chromosomes Cancer 1994, 11:1-6.
87. Lumbiganon P., Rugpao S., Phandhu-fung S., Laopaiboon M., Vudhikamraksa N., Werawatakul Y. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicenter case-control study. Br J Obstet Gynaecol 1996, 103:909-914.
88. Romieu I., Walker A.M., Jick S. Determinants of uterine fibroids. Post Mark Surveill 1991, 5:119-133.
89. Marshall L.M., Spiegelman D., Goldman M.B., Manson J.E., Colditz G.A., Barbieri R.L., et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998, 70:432-439.
90. Wise L.A., Palmer J.R., Harlow B.L., Spiegelman D., Stewart E.A., Adams-Campbell L.L., et al. Reproductive factors, hormonal contraception and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004, 159:113-123.
91. Faerstein E., Szklo M., Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol 2001, 153:1-10.
92. Terry K.L., De Vivo I., Hankinson S.E., Missmer S.A. Reproductive characteristics and risk of uterine leiomyomata. Fertil Steril 2010, 94:2703-2707.
93. Dragomir A.D., Schroeder J.C., Connolly A., Kupper L.L., Hill M.C., Olshan A.F., et al. Potential risk factors associated with subtypes of uterine leiomyomata. Reprod Sci 2010, 17:1029-1035.
94. Marino J.L., Eskenazi B., Warner M., Samuels S., Vercellini P., Gavoni N., et al. Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. Hum Reprod 2004, 19:2350-2355.
95. Chen C.R., Buck G.M., Courey N.G., Perez K.M., Wactawski-Wende J. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol 2001, 153:20-26.
96. Parazzini F., La Vecchia C., Negri E., Cecchetti G., Fedele L. Epidemiological characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol 1988, 72:853-857.
97. Samadi A.R., Lee N.C., Flanders W.D., Boring J.R., Parris E.B. Risk factors for self-reported uterine fibroids: a case-control study. Am J Public Health 1996, 86:858-862.
98. Parazzini F. Risk factors for clinically diagnosed uterine fibroids in women around menopause. Maturitas 2006, 55:174-179.
99. Cramer S.F., Patel A. The frequency of uterine leiomyoma. Am J Clin Pathol 1990, 94:435-438.
100. Kawaguchi K., Fujii S., Konishi I., Iwai T., Nanbu Y., Nongaki H., et al. Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Arch A Pathol Anat Histopathol 1991, 419:309-315.
101. Parazzini F., Negri E., La Vecchia C., Chatenoud L., Ricci E., Guarnerio P. Reproductive factors and risk of uterine fibroids. Epidemiology 1996, 7:440-442.
102. Baird D.D., Dunson D.B. Why is parity protective for uterine fibroids?. Epidemiology 2003, 14:247-250.
103. Bernstein L., Pike M.C., Ross R.K., Judd H.L., Brown J.B., Henderson B.E. Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. J Natl Cancer Inst 1985, 74:741-745.
104. Dorgan J.F., Reichman M.E., Judd J.T., Brown C., Longcope C., Schatzkin A., et al. Relationships of age and reproductive characteristics with plasma estrogen and androgens in premenopausal women. Cancer Epidemiol Biomarkers Prev 1995, 4:381-386.
105. Musey V.C., Collins D.C., Brogan D.R., Santos V.R., Musey P.I., Martino-Saltzman D., et al. Long term effects of a first pregnancy on the hormonal environment: estrogens and androgens. J Clin Endocrinol Metab 1987, 64:111-118.
106. Burbank F. Childbirth and myoma treatment by uterine artery occlusion: do they share a common biology?. Journal of the American Association of Gynecological Laparoscopists 2004, 11:138-152.
107. Laughlin S.K., Hartmann K.E., Baird D.D. Postpartum factors and natural fibroid regression. Am J Obstet Gynecol 2011, 204(496):e1-e6.
108. Marshall L.M., Spiegelman D., Manson J.E., Goldman M.B., Barbieri R.L., Stampfer M.J., et al. Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. Epidemiology 1998, 9:511-517.
109. Wise L.A., Palmer J.R., Spiegelman D., Harlow B.L., Stewart E.A., Adams-Campbell L.L., et al. Influence of body size and body fat distribution on risk of uterine leiomyomata in US black women. Epidemiology 2005, 16:346-354.
110. Takeda T., Sakata M., Isobe A., Miyake A., Nishmoto F., Ota Y., et al. Relationship between metabolic syndrome and uterine leiomyomas: a case-control study. Gynecol Obstet Invest 2008, 66:14-17.
111. Terry K.L., De Vivo I., Hankinson S.E., Spiegelman D., Wise L.A., Missmer S.A. Anthropometric characteristics and risk of uterine leiomyoma. Epidemiology 2007, 18:758-763.
112. Baird D.D., Dunson D.B., Hill M.C., Cousins D., Schectman J.M. Association of physical activity with development of uterine leiomyoma. Am J Epidemiol 2007, 165:157-163.
113. Azziz R. Reproductive endocrinological alterations in female asymptomatic obesity. Fertil Steril 1989, 52:703-725.
114. Pasquali R., Gambineri A. Metabolic effects of obesity on reproduction. Reprod Biomed Online 2006, 12:542-551.
115. Wyshak G., Frisch R.E., Albright N.L., Albright T.E., Schiff I. Lower prevalence of benign diseases of the breast and benign tumors of the reproductive system among former college athletes compared to non-athletes. Br J Cancer 1986, 54:841-845.
116. Tworoger S.S., Missmer S.A., Eliassen A.H., Barbieri R.L., Dowsett M., Hankinson S.E. Physical activity and inactivity in relation to sex hormone, prolactin, and insulin-like growth factor concentrations in premenopausal women - exercise and premenopausal hormones. Cancer Causes Control 2007, 18:743-752.
117. Barbieri R.L., McShane P.M., Ryan K.J. Constituents of cigarette smoke inhibit human granulosa cell aromatase. Fertil Steril 1986, 46:232-236.
118. Michnovicz J.J., Hershcopf R.J., Nagunuma H., Bradlow H.L., Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med 1986, 315:1305-1309.
119. Bradlow L. Variations in estrogen metabolism. Steroid contraceptives and women's response 1994, 171-178. Plenum Press, New York. R. Snow, P. Hall (Eds.).
120. Ohtake F., Takeyama K., Matsumoto T., Kitagawa H., Yamamoto Y., Nohara K., et al. Modulation of oestrogen receptor signaling by association with the activated dioxin receptor. Nature 2003, 423:545-550.
121. Parazzini F., Negri E., La Vecchia C., Rabaiotti M., Luchini L., Villa A., et al. Uterine myomas and smoking. Results from an Italian study. J Reprod Med 1996, 41:316-320.
122. Katsouyami K., Boyle P., Trichopoulos D. Diet and urine estrogens among postmenopausal women. Oncology 1991, 48:490-494.
123. Reichman M.E., Judd J.T., Longcope C., Schatzkin A., Clevidence B.A., Nair P.P., et al. Effects of alcohol consumption on plasma and urinary hormone concentrations in premenopausal women. J Natl Cancer Inst 1993, 85:722-727.
124. Nagata C., Nakamura K., Oba S., Hayashi M., Takeda N., Yasuda K. Association of intakes of fat, dietary fiber, soya isoflavones and alcohol with uterine fibroids in Japanese women. Br J Nutr 2009, 101:1427-1431.
125. Chiaffarino F., Parazzini F., La Vecchia C., Chatenoud L., Di Cintio E., Marsico S. Diet and uterine myomas. Obstet Gynecol 1999, 94:395-398.
126. Lucero J., Harlow B.L., Barbieri R.L., Sluss P., Cramer D.W. Early follicular phase hormone levels in relation to patterns of alcohol, tobacco, and coffee use. Fertil Steril 2001, 76:723-729.
127. Leonard T.K., Watson R.R., Mohs M.E. The effects of caffeine on various systems: a review. J Am Diet Assoc 1987, 87:1048-1053.
128. Michnovicz J.J., Bradlow H.L. Dietary and pharmacological control of estradiol metabolism in humans. Ann NY Acad Sci 1990, 595:291-299.
129. Longcope C. Diet and estrogen metabolism. Steroid contraceptives and women's response 1994, 143-152. Plenum Press, New York. R. Snow, P. Hall (Eds.).
130. Atkinson C., Lampe J.W., Scholes D., Chen C., Wahala K., Schwartz S.M. Lignan and isoflavone excretion in relation to uterine fibroids: a case-control study of young to middle-aged women in the United States. Am J Clin Nutr 2006, 84:587-593.
131. Wise L.A., Radin R.G., Palmer J.R., Kumanyika S.K., Rosenberg L. A prospective study of dairy intake and risk of uterine leiomyomata. Am J Epidemiol 2010, 171:221-232.
132. Wise L.A., Radin R.G., Palmer J.R., Kumanyika S.K., Boggs D.A., Rosenberg L. Intake of fruit, vegetables, and carotenoids in relation to risk of uterine leiomyomata. Am J Clin Nutr 2011, 94:1620-1631.
133. Sahin K., Ozercan R., Onderci M., Sahin N., Khachik F., Seren S., et al. Dietary tomato powder supplementation in the prevention of leiomyoma of the oviduct in the Japanese quail. Nutr Cancer 2007, 59:70-75.
134. Terry K.L., Missmer S.A., Hankinson S.E., Willett W.C., De Vivo I. Lycopene and other carotenoid intake in relation to risk of uterine leiomyomata. Am J Obstet Gynecol 2008, 198(37):e1-e8.
135. Baird D.D., Kesner J.S., Dunson D.B. Luteinizing hormone in premenopausal women may stimulate uterine leiomyomata development. J Soc Gynecol Investig 2006, 13:130-135.
136. Van der Ven L.T., Van Buul-Offers S.C., Gloudemans T., Bloemen R.J., Roholl P.J., Sussenbach J.S., et al. Modulation of insulin-like growth factor (IGF) action by IGF-binding proteins in normal, benign, and malignant smooth muscle tissues. J Clin Endocrinol Metab 1996, 81:3629-3635.
137. Strawn E.Y., Novy M.J., Burry K.A., Bethea C.L. Insulin-like growth factor I promotes leiomyoma cell growth in vitro. American Journal of Obstetrics and Gynecology 1995, 172:1837-1844.
138. Boehm KD, Daimon M, Gorodeski I.G., Sheean L.A., Utiann W.H., Ilan J. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol Reprod Dev 1990, 27:93-101.
139. Giudice L.C., Irwin J.C., Dsupin B.A., Pannier E.M., Jin I.H., Vu T.H., et al. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod 1993, 8:1796-1806.
140. Englund K., Lindblom B., Carlstrom K., Gustavsson I., Sjoblom P., Blanck A. Gene expression and tissue concentrations of IGF-I in human myometrium and fibroids under different hormonal conditions. Mol Hum Reprod 2000, 6:915-920.
141. Dixon D., He H., Haseman J.K. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environmental Health Perspectives 2000, 108:795-802.
142. Wolanska M., Bankowski E. An accumulation of insulin-like growth factor I (IGF-I) in human myometrium and uterine leiomyomas in various stages of tumor growth. Eur Cytokine Netw 2004, 15:359-363.
143. Radin R.G., Palmer J.R., Rosenberg L., Kumanyika S.K., Wise L.A. Dietary glycemic index and load in relation to risk of uterine leiomyomata in the black women's health study. Am J Clin Nutr 2010, 91:1281-1288.
144. Wise L.A., Palmer J.R., Stewart E.A., Rosenberg L. Polycystic ovary syndrome and risk of uterine leiomyomata. Fertil Steril 2007, 87:1108-1115.
145. Walocha J.A., Litwin J.A., Miodonski A.J. Vascular system of intramural leiomyomata revealed by corrosion casting and scanning electron microscopy. Hum Reprod 2003, 18:1088-1093.
146. Baird D., Wise L.A. Childhood abuse and fibroids. Epidemiology 2011, 22:15-17.
147. Ferin M. Clinical review 105: stress and the reproductive cycle. J Clin Endocrin Metab 1999, 84:1768-1774.
148. Puder J.J., Freda P.U., Goland R.S., Ferin M., Wardlaw S.L. Stimulatory effects of stress on gonadotropin secretion in estrogen-treated women. J Clin Endocrin Metab 2000, 85:2184-2188.
149. Kornya L., Bodis J., Koppan M., Tinneberg H.R., Torok A. Modulatory effect of acetylcholine on gonadotropin-stimulated human granulosa cell steroid secretion. Gynecol Obstet Invest 2001, 52:104-107.
150. Wise L.A., Palmer J.R., Cozier Y.C., Hunt M.O., Stewart E.A., Rosenberg L. Perceived racial discrimination and risk of uterine leiomyomata. Epidemiology 2007, 18:747-757.
151. Vines A.I., Ta M., Esserman D.A. The association between self-reported major life events and the presence of uterine fibroids. Women's Health Issues 2010, 20:294-298.
152. Boynton-Jarrett R., Rich-Edwards J.W., Jun H.-J., Hibert E.N., Wright R.J. Abuse in childhood and risk of uterine leiomyoma: the role of emotional support in biological resilience. Epidemiology 2011, 22:6-14.
153. Parazzini F., Negri E., La Vecchia C., Fedele L., Rabaiotti M., Luchini L. Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol 1992, 79:430-433.
154. Chiaffarino F., Parazzini F., La Vecchia C., Marsico S., Surace M., Ricci E. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol 1999, 106:857-860.
155. Ramcharan S., Pelligrin F.A., Ray R., et al. The Walnut Creek contraceptive drug study. A prospective study of the side effects of oral contraceptives. Center Popul Res Monogr 1981, 69-74.
156. Royal College of General Practitioners Oral contraceptives and health: an interim report from the oral contraception study of the Royal College of General Practitioners 1974, Pittman Medical, London.
157. Winter L., Goldy A.S., Baer C. Prevalence and epidemiological correlates of Chlamydia trachomatis in rural and urban populations. Sex Transm Dis 1990, 17:30-36.
158. Clark M.K., Sowers M.F., Levy B.T., Tenhundfeld P. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril 2001, 75:871-877.
159. Newbold R. Cellular and molecular effects of developmental exposure to diethylstilbestrol: implications for other environmental estrogens. Environmental Health Perspectives 1995, 103:83-87.
160. Greathouse K.L., Cook J.D., Lin K., Davis B.J., Berry T.D., Bredfeldt T.G., et al. Identification of uterine leiomyoma genes developmentally reprogrammed by neonatal exposure to diethylstilbestrol. Reprod Sci 2008, 15:765-778.
161. Missmer S.A., Hankinson S.E., Spiegelman D., Barbieri R.L., Michels K.B., Hunter D.J. In utero exposures and the incidence of endometriosis. Fertil Steril 2004, 82:1501-1508.
162. Baird D.D., Newbold R. Prenatal diethylstilbestrol (DES) exposure is associated with uterine leiomyoma development. Reprod Toxicol 2005, 20:81-84.
163. Witherspoon J.T. A possible cause of uterine fibroids. Endocrinology (Baltimore) 1933, 17:703-708.
164. Witherspoon J.T., Butler V.W. The etiology of uterine fibroids. Surg Gynecol Obstet 1934, 58:57-61.
165. Cramer S.F., Padela A.I., Marchetti C.E., Newcomb P.M., Heller D.S. Myometrial hyperplasia in pediatric, adolescent, and young adult uteri. J Pediatr Adolesc Gynecol 2003, 16:301-306.
166. Faerstein E., Szklo M., Rosenshein N.B. Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol 2001, 153:11-19.
167. Vikhlyaeva E.M., Khodzhaeva Z.S., Fantschenko N.D. Familial predisposition to uterine leiomyomas. Int J Gynaecol Obstet 1995, 51:127-131.
168. Kurbanova M.K.H., Koroleva A.G., Sergeev A.S. Genetic-epidemiological analysis of uterine myoma: assessment of repeated risk. Genetika 1989, 25:1896-1898.
169. Treloar S.A., Martin N.G., Dennerstein L., Raphael B., Heath A.C. Pathways to hysterectomy: insights from longitudinal twin research. Am J Obstet Gynecol 1992, 167:82-88.
170. Reed W.B., Walker R., Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol 1973, 53:409-416.
171. Garcia Muret M.P., Pujol R.M., Alomar A., Calaf J., de Moragas J.M. Familial leiomyomatosis cutis et uteri (Reed's syndrome). Arch Derm Res 1988, 280:S29-S32.
172. Launonen V., Vierimaa O., Kiuru M., Isola J., Roth S., Pukkala E., et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 2001, 98:3387-3392.
173. Van Voorhis B.J., Romitti P.A., Jones M.P. Family history as a risk factor for development of uterine leiomyomas. Results of a pilot study. J Reprod Med 2002, 47:663-669.
174. Kiuru M., Launonen V., Hietala M., Aittomaki K., Vierimaa O., Salovaara R., et al. Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol 2001, 159:825-829.
175. Alam N.A., Rowan A.J., Wortham N.C., Pollard P.J., Mitchell M., Tyrer J.P., et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 2003, 12:1241-1252.
176. Colgan T.J., Pron G., Mocarski E.J., Bennett J.D., Asch M.R., Common A. Pathological features of uteri and leiomyomas following uterine artery embolization for leiomyomas. Am J Surg Pathol 2003, 27:167-177.
177. Tomlinson I.P., Alam N.A., Rowan A.J., Barclay E., Jaeger E.E., Kelsell D., et al. The multiple leiomyoma consortium. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002, 30:406-410.
178. Martinez-Mir A., Glaser B., Chuang G.S., Horev L., Waldman A., Engler D.E., et al. Germline fumarate hydratase mutations in families with multiple cutaneous and uterine leiomyomata. J Invest Dermatol 2003, 121:741-744.
179. Lehtonen R., Kiuru M., Vanharanta S., Sjoberg J., Aaltonen L.M., Aittomaki K., et al. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol 2004, 164:17-22.
180. Kiuru M., Lehtonen R., Arola J., Salovaara R., Jarvinen H., Aittomaki K., et al. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res 2002, 62:4554-4557.
181. Barker K.T., Bevan S., Wang R., Lu Y.J., Flanagan A.M., Bridge J.A., et al. Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas. Br J Cancer 2002, 87:446-448.
182. Gross K.L., Panhuysen C.I., Kleinman M.S., Goldhammer H., Jones E.S., Nassery N., et al. Involvement of fumarate hydratase in nonsyndromic uterine leiomyomas: genetic linkage analysis and FISH studies. Genes Chrom Cancer 2004, 41:183-190.
183. Chuang G.S., Martinez-Mir A., Geyer A., Engler D.E., Glaser B., Cserhalmi-Friedman P.B., et al. Germline fumarate hydratase mutations and evidence for a founder mutation underlying multiple cutaneous and uterine leiomyomata. J Am Acad Dermatol 2005, 52:410-416.
184. Shveiky D., Rojansky N., Ben Bassat H., Ben Meir A., Klein B., Shushan A. Family history of uterine fibroids associated with low level of fumarate hydratase in leiomyomata cells. Eur J Obstet Gynecol Reprod Biol 2009, 146:234-235.
185. Stewart L., Glenn G.M., Stratton P., Goldstein A.M., Merino M.J., Tucker M.A., et al. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. Arch Dermatol 2008, 144:1584-1592.
186. Gross K., Morton C., Stewart E.A. Finding genes for uterine fibroids [abstract]. Obstet Gynecol 2000, 95:S60.
187. Huyck K.L., Panhuysen C.I.M., Cuenco K.T., Zhang J., Goldhammer H., Jones E.S., et al. The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters. American Journal of Obstetrics and Gynecology 2008, 198(168):e1-e9.
188. Risch N., Merikangas K. The future of genetic studies of complex human diseases. Science 1996, 273:1516-1517.
189. Al-Hendy A., Salama S.A. Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig 2006, 13:136-144.
190. Denschlag D., Bentz E.-K., Hefler L., Pietrowski D., Zeillinger R., Tempfer C., et al. Genotype distribution of estrogen receptor-alpha, catechol-O-methyltransferase, and cytochrome P450 17 gene polymorphisms in Caucasian women with uterine leiomyomas. Fertility and Sterility 2006, 85:462-467.
191. Gooden K.M., Schroeder J.C., North K.E., Gammon M.D., Hartmann K.E., Taylor J., et al. Val153Met polymorphism of catechol-O-methyltransferase and prevalence of uterine leiomyomata. Reprod Sci 2007, 14:117-120.
192. Salama S.A., Ho S.L., Wang H.Q., Tenhunen J., Tilgmann C., Al-Hendy A. Hormonal regulation of catechol-O-methyl transferase activity in women with uterine leiomyomas. Fertil Steril 2006, 86:259-262.
193. Massart F., Becherini L., Gennari L., Facchini V., Genezzani A.R., Brandi M.L. Genotype distribution of estrogen receptor-alpha gene polymorphisms in Italian women with surgical uterine leiomyomas. Fertil Steril 2001, 75:567-570.
194. Kitawaki J., Obayashi H., Ishibara H., Koshiba H., Kusuki I., Kaso N.E.A. Oestrogen receptor-alpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. Human Reprod 2001, 16:51-55.
195. Hsieh Y.Y., Chang C.C., Tsai F.J., Tsai H.D., Yeh L.S., Lin C.C., et al. Estrogen receptor thymine-adenine dinucleotide repeat polymorphism is associated with susceptibility to leiomyoma. Fertil Steril 2003, 79:96-99.
196. Massart F., Becherini L., Marini F., Noci I., Piciocchi L., Del Monte F., et al. Analysis of estrogen receptor (ERalpha and ERbeta) and progesterone receptor (PR) polymorphisms in uterine leiomyomas. Med Sci Monit 2003, 9:BR25-BR30.
197. Villanova F.E., Andrade P.M., Otsuka A.Y., Gomes M.T.V., Leal E.S., Castro R.A., et al. Estrogen receptor alpha polymorphism and susceptibility to uterine leiomyoma. Steroids 2006, 71:960-965.
198. Al-Hendy A., Salama S.A. Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril 2006, 86:686-693.
199. El-Shennawy G.A., Elbialy A.A., Isamil A.E., El Behery M.M. Is genetic polymorphism of ER-alpha, CYP1A1, and CYP1B1 a risk factor for uterine leiomyoma?. Arch Gynecol Obstet 2011, 283:1313-1318.
200. Amant F., Dorfling C.M., de Brabanter J., Vandewalle J., Vergote I., Lindeque B.G., et al. A possible role of the cytochrome P450c17alpha gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study. Acta Obstet Gynecol Scand 2004, 83:234-239.
201. Pakiz M., Potocnik U., But I. Solitary and multiple uterine leiomyomas among Caucasian women: two different disorders?. Fertil Steril 2010, 94:2291-2295.
202. Tsujino T., Ohara N., Yoshida S., Kennedy S., Takemura N., Deguchi M., et al. The CYP17 MspA1 polymorphism is not associated with an increased risk of uterine leiomyomas in a Japanese population. Gynecol Endocrinol 2006, 22:87-91.
203. Vieira L.C., Gomes M.T., Castro Rde A., de Souza N.C., da Silva I.D., Baracat E.C., et al. Association of the CYP17 gene polymorphism with risk for uterine leiomyoma in Brazilian women. Gynecol Endocrinol 2008, 24:373-377.
204. Ye Y., Cheng X., Luo H.B., Liu L., Li Y.B., Hou Y.P. CYP1A1 and CYP1B1 genetic polymorphisms and uterine leiomyoma risk in Chinese women. J Assist Reprod Genet 2008, 25:389-394.
205. Rosa F.E., Canevari Rde A., Ambrosio E.P., Ramos Cirilo P.D., Pontes A., Rainho C.A., et al. Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas. Clin Chem Lab Med 2008, 46:814-823.
206. Kado N., Kitawaki J., Obayashi H., Ishihara H., Koshiba H., Kusuki I., et al. Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. Hum Reprod 2002, 17:897-902.
207. Patterson N., Hattangadi N., Lane B., Lohmueller K.E., Hafler D.A., Oksenberg J.R., et al. Methods for high-density admixture mapping of disease genes. Am J Hum Genet 2004, 74:979-1000.
208. Cha P.C., Takahashi A., Hosono N., Low S.K., Kamatani N., Kubo M., et al. A genome-wide association study identifies three loci associated with susceptibility to uterine fibroids. Nat Genet 2011, 43:447-450.
209. Luoto R., Rutanen E.M., Auvinen A. Fibroids and hypertension - A cross-sectional study of women undergoing hysterectomy. J Reprod Med 2001, 46:359-364.
210. Silver M.A., Raghuvir R., Fedirko B., Elser D. Systemic hypertension among women with uterine leiomyomata: potential final common pathways of target end-organ remodeling. J Clin Hypertens (Greenwich) 2005, 7:664-668.
211. Settnes A., Andreasen A.H., Jorgensen T. Hypertension is associated with an increased risk for hysterectomy: a Danish cohort study. Eur J Obstet Gynecol Reprod Biol 2005, 122:218-224.
212. Boynton-Jarrett R., Rich-Edwards J., Malspeis S., Missmer S.A., Wright R. A prospective study of hypertension and risk of uterine leiomyomata. Am J Epidemiol 2005, 161:628-638.
213. Radin R.G., Rosenberg L., Palmer J.R., Cozier Y.C., Kumanyika S.K., Wise L.A. Hypertension and risk of uterine leiomyomata in US black women. Hum Reprod 2012, 27:1504-1509.
214. Jackson L.W., Zullo M.D., Goldberg J.M. The association between heavy metals, endometriosis and uterine myomas among premenopausal women: National Health and Nutrition Examination Survey 1999-2002. Hum Reprod 2008, 23:679-687.
215. Gomez-Duran A., Carvajal-Gonzalez J.M., Mulero-Navarro S., Santiago-Josefat B., Puga A., Fernandez-Salguero P.M. Fitting a xenobiotic receptor into cell homeostasis: how the dioxin receptor interacts with TGFbeta signaling. Biochem Pharmacol 2009, 77:700-712.
216. Lambertino A., Turyk M., Anderson H., Freels S., Persky V. Uterine leiomyomata in a cohort of Great Lakes sport fish consumers. Environ Res 2011, 111:565-572.
217. Hauser R., Calafat A.M. Phthalates and human health. Occup Environ Med 2005, 62:806-818.
218. Weuve J., Hauser R., Calafat A.M., Missmer S.A., Wise L.A. Association of exposure to phthalates with endometriosis and uterine leiomyomata: findings from NHANES, 1999-2004. Environ Health Perspect 2010, 118:825-832.
219. Huang P.C., Tsai E.M., Li W.F., Liao P.C., Chung M.C., Wang Y.H., et al. Association between phthalate exposure and glutathione S-transferase M1 polymorphism in adenomyosis, leiomyoma and endometriosis. Hum Reprod 2010, 25:986-994.
220. Carlson K.J., Miller B.A., Fowler F.J. The Maine women's health study: II. Outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic pain. Obstet Gynecol 1994, 83:566-572.
221. Weber A.M., Mitchinson A.R., Gidwani G.P., Mascha E., Walters M.D. Uterine myomas and factors associated with hysterectomy in premenopausal women. Am J Obstet Gynecol 1997, 176:1213-1217. discussion 7-9.
222. Candiani G.B., Fedele L., Parazzini F., Villa L. Risk of recurrence after myomectomy. British Journal of Obstetrics & Gynaecology 1991, 98:385-389.
223. Fedele L., Parazzini F., Luchini L., Mezzopane R., Tozzi L., Villa L. Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study. Hum Reprod 1995, 10:1795-1796.
224. Hanafi M. Predictors of leiomyoma recurrence after myomectomy. Obstet Gynecol 2005, 105:877-881.
225. van der Kooij SM, Hehenkamp WJ, Volkers NA, Birnie E Ankum WM, Reekers JA. Uterine artery embolization vs. hysterectomy in the treatment of symptomatic uterine fibroids: 5-year outcome from the randomized EMMY trial.Am J Obstet Gynecol 2011;205:317.
226. Marret H., Cottier J.P., Alonso A.M., Giraudeau B., Body G., Herbreteau D. Predictive factors for fibroids recurrence after uterine artery embolisation. Bjog 2005, 112:461-465.
227. Broder M.S., Goodwin S., Chen G., Tang L.J., Costantino M.M., Nguyen M.H., et al. Comparison of long-term outcomes of myomectomy and uterine artery embolization. Obstet Gynecol 2002, 100:864-868.
228. Goodwin S.C., Spies J.B., Worthington-Kirsch R., Peterson E., Pron G., Li S., et al. Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol 2008, 111:22-33.
229. Pron G., Mocarski E., Bennett J., Vilos G., Common A., Vanderburgh L. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial. Obstet Gynecol 2005, 105:67-76.
230. Funaki K., Fukunishi H., Sawada K. Clinical outcomes of magnetic resonance-guided focused ultrasound surgery for uterine myomas: 24-month follow-up. Ultrasound Obstet Gynecol 2009, 34:584-589.
231. Stewart E.A., Gostout B., Rabinovici J., Kim H.S., Regan L., Tempany C.M. Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet Gynecol 2007, 110:279-287.
232. Mizutani T., Sugihara A., Honma H., Komura H., Nakamuro K., Terada N. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy. Gynecol Endocrinol 2005, 20:80-83.
233. Lee B.S., Margolin S.B., Nowak R.A. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 1998, 83:219-223.
234. Zhang D., Al-Hendy M., Richard-Davis G., Montgomery-Rice V., Sharan C., Rajaratnam V., et al. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol 2010, 202(289):e1-e9.
235. Malik M., Webb J., Catherino W.H. Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells. Clin Endocrinol (Oxf) 2008, 69:462-470.
236. Baird D.D. Hypothesis: vitamin D protects against uterine fibroid development [Abstract]. Ann Epidemiol 2008, 18:710.
237. Blauer M., Rovio P.H., Ylikomi T., Heinonen P.K. Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro. Fertil Steril 2009, 91:1919-1925.
238. Sharan C., Halder S.K., Thota C., Jaleel T., Nair S., Al-Hendy A. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril 2011, 95:247-253.
239. Halder S.K., Goodwin J.S., Al-Hendy A. 1,25-Dihydroxyvitamin D3 reduces TGFβ3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 2011, 96:E754-E762.
240. Tsuda H., Kawabata M., Nakamoto O., Yamamoto K. Clinical predictors in the natural history of uterine leiomyoma: preliminary study. J Ultrasound Med 1998, 17:17-20.